Strong grip strength may protect against obesity-related complicationsStrong grip strength may protect against obesity-related complications
People with excess body fat who build and keep muscle may be less likely to develop obesity-induced heart, liver, or kidney damage or die early, according to a new study published in The Journal of Clinical Endocrinology & Metabolism.
GLP-1 drugs may delay alcohol’s effects in the bloodstreamGLP-1 drugs may delay alcohol’s effects in the bloodstream
There’s mounting evidence that popular drugs prescribed for diabetes management and weight loss—better known by trade names like Ozempic and Wegovy—could be effective in reducing alcohol use. There’s mounting evidence that popular drugs prescribed for diabetes management and weight loss—better known by trade names like Ozempic and Wegovy—could be effective in reducing alcohol use.
Medicare Decision on GLP-1s Soon; Inhaled Insulin Under Review for Kids; ‘Manopause’Medicare Decision on GLP-1s Soon; Inhaled Insulin Under Review for Kids; ‘Manopause’
(MedPage Today) — CMS Administrator Mehmet Oz, MD, MBA, said his agency will make an announcement on potential Medicare coverage of GLP-1 receptor agonists “very soon.” (CNBC) Preclinical studies “have consistently demonstrated the potential… (MedPage Today) — CMS Administrator Mehmet Oz, MD, MBA, said his agency will make an announcement on potential Medicare coverage Read More
Medicare Decision on GLP-1s Soon; Inhaled Insulin Under Review for Kids; ‘Manopause’Medicare Decision on GLP-1s Soon; Inhaled Insulin Under Review for Kids; ‘Manopause’
(MedPage Today) — CMS Administrator Mehmet Oz, MD, MBA, said his agency will make an announcement on potential Medicare coverage of GLP-1 receptor agonists “very soon.” (CNBC) Preclinical studies “have consistently demonstrated the potential… (MedPage Today) — CMS Administrator Mehmet Oz, MD, MBA, said his agency will make an announcement on potential Medicare coverage […]
American Cancer Society Research Grantee Improving Breast Cancer Screening & Care ExperienceAmerican Cancer Society Research Grantee Improving Breast Cancer Screening & Care Experience
Post Content Post Content
GLP-1 Drugs Associated With Lower Overall Cancer RiskGLP-1 Drugs Associated With Lower Overall Cancer Risk
Obesity is a risk factor for several forms of cancer that comprise 40% of annual cancer diagnoses in the US. New findings published in JAMA Oncology suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may help protect against some of these cancer types. Obesity is a risk factor for several forms of cancer that comprise 40% Read More
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection FractionSemaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
This study evaluates the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction in clinical practice. This study evaluates the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction in clinical practice.
New Molecules and Indications for GLP-1 MedicinesNew Molecules and Indications for GLP-1 Medicines
This Perspective explores recent progress and future directions in glucagon-like peptide-1 medicines. This Perspective explores recent progress and future directions in glucagon-like peptide-1 medicines.
Social Adversity and Triple-Negative Breast Cancer Incidence Among Black WomenSocial Adversity and Triple-Negative Breast Cancer Incidence Among Black Women
This cohort study investigates the association between social adversity and incidence of triple-negative breast cancer among US Black women.
How Do GLP-1 Drugs Stack Up for Cardiorenal Benefits in Diabetes?How Do GLP-1 Drugs Stack Up for Cardiorenal Benefits in Diabetes?
(MedPage Today) — Three GLP-1 receptor agonists had generally comparable cardiorenal outcomes when used in type 2 diabetes, a retrospective comparative effectiveness study indicated. Among 21,790 military veterans with diabetes, initiators of… (MedPage Today) — Three GLP-1 receptor agonists had generally comparable cardiorenal outcomes when used in type 2 diabetes, a retrospective comparative effectiveness Read More